Progress in Radiopharmacy

1. Future development of radiopharmaceuticals.- One: Brain receptor ligands.- 2. Necessary conditions for a multicenter study with a new radiopharmaceutical. Example: 123 I-Iomazenil.- 3. Design and evaluation of new receptor ligands exemplified by recent developments in the pharmacology of the benzodiazepine receptor.- 4. Studies on substituted benzamides as brain dopamine receptor imaging agent.- Two: Technetium-99m and other radionuclide generators.- 5. Cell labeling in radiopharmacy: what can radiolabeled monoclonal antibodies offer?.- 6. Automated systems for the preparation of Tc-kits in hospitals.- 7. New radiopharmaceuticals based on Technetium.- 8. The development of new radionuclide generator systems for nuclear medicine applications.- Three: Positron Emission Tomography.- 9. Production and application of oxygen-15; radiopharmacy aspects.- 10. Clinical aspects of positron emission tomography.- 11. Carbon-11 radiopharmaceuticass - radiopharmacy aspects.- 12. Production and distribution of 18F-radiopharmaceuticals - 2-deoxy-2[18F]fluoro-D-Glucose — radiopharmaceutic aspects.- 13. Preclinical data necessary to assess PET examinations.- Four: Rules and regulations.- 14. EEC directives and radiopharmaceuticals: the point of view of the radiopharmaceutical industry.- 15. European regulations and guidelines for the registration of radiopharmaceuticals.- 16. General guidelines for the quality assurance and quality control of short-lived radiopharmaceuticals.- 17. Legal and regulatory aspects of PET radiopharmaceuticals in the USA.- Five: Education.- 18. The development of a co-ordinated training programme in radiopharmacy in Europe.- 19. Experiences in postgraduate education of radiochemists and radiopharmacists at Berlin- Buch.- Six: Appendix.- 20. Monoclonalchimeric antibodies to HIV-1 - Clinical perspectives.- 21. Tracer technique - the Swiss story.